Ranitidine, at doses of 300 mg b.i.d., brings about a pronounced inhibition of both daytime and nocturnal acid secretion. The aim of the present open study, conducted in 68 patients with peptic lesions of the upper gastrointestinal tract, was to assess whether or not ranitidine at 300 mg b.i.d. for 4 weeks was capable of healing these lesions, which had failed to respond to treatment with H2-antagonists at standard doses, even when administered over fairly lengthy periods (greater than 8 weeks). The results obtained show that the 300 mg b.i.d. regimen yields a marked gain in terms of healing of lesions and relief of symptoms (achieved in roughly 80% of cases), accompanied by excellent tolerance. It is concluded that a double dose of ranitidine is clinically justified in particular cases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
An Indirect Treatment Comparison of Lenvatinib for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma.
Adv Ther
December 2024
Source Health Economics, London, UK.
Introduction: This study compared the relative efficacy of first-line lenvatinib, a standard-of-care treatment for unresectable hepatocellular carcinoma (uHCC), vs licensed/license in-progress comparators. Using inverse probability of treatment weighting (IPTW) and network meta-analysis (NMA), updated evidence for lenvatinib monotherapy from LEAP-002, in addition to evidence from REFLECT, was included in the analyses.
Methods: Randomized controlled trials (RCTs) were identified via systematic review.
Safety, Pharmacokinetics and Antiviral Efficacy of Capsid Assembly Modulator Freethiadine in Healthy Volunteers and Chronic Hepatitis B Patients.
Liver Int
January 2025
Phase I Clinical Trial Center, the First Hospital of Jilin University, Jilin, China.
Background And Aims: Freethiadine is a novel hepatitis B virus capsid assembly modulator. Herein, we report the safety, tolerability, pharmacokinetics and 28-day antiviral activities of freethiadine.
Methods: The study consisted of two parts.
Stability and Reliability of Repeated Plasma Pregnenolone Levels After Oral Pregnenolone Dosing in Individuals with Cocaine Use Disorder: Pilot Findings.
Life (Basel)
November 2024
The Yale Stress Center, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA.
Substance use disorders (SUDs), including cocaine use disorder (CUD), have significant negative health risks and impose a substantial social burden, yet effective treatments are limited. Pregnenolone, a neuroactive steroid precursor, has been shown to reduce alcohol craving and normalize stress biology in individuals with CUD, but its clinical utility has been questioned due to limited data on bioavailability and the stability of blood levels in humans. Thus, this pilot study aimed to determine whether twice-daily oral pregnenolone (PREG) at 300 mg/day and 500 mg/day versus placebo in week two of PREG administration led to stable increased plasma pregnenolone levels in individuals with CUD.
View Article and Find Full Text PDFExposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.
CPT Pharmacometrics Syst Pharmacol
November 2024
Pfizer Research and Development, New York, New York, USA.
Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis describe a collection of liver conditions characterized by the accumulation of liver fat. Despite biopsy being the reference standard for determining the severity of disease, non-invasive measures such as magnetic resonance imaging proton density fat fraction (MRI-PDFF) and FibroScan® controlled attenuation parameter (CAP™) can be used to understand longitudinal changes in steatosis. The aim of this work was to describe the exposure-response relationship of ervogastat with or without clesacostat on steatosis, through population pharmacokinetic/pharmacodynamic (PK/PD) modeling of both liver fat measurements simultaneously.
View Article and Find Full Text PDFOpen-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors.
Target Oncol
November 2024
Sarah Cannon Research Institute, Nashville, TN, USA.
Background: Adavosertib (AZD1775) is a small-molecule Wee1 inhibitor. Durvalumab is a PD-L1 inhibitor.
Objective: The safety, tolerability, pharmacokinetics, and preliminary antitumor activity of adavosertib plus durvalumab were evaluated in patients with refractory solid tumors to define the maximum tolerated dose (MTD) and recommended phase II dose (RP2D).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!